The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Toward individualized breast cancer screening strategies—TMIST

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

On behalf of the ECOG-ACRIN Cancer Research Group

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Etta D. Pisano, MD
Principal investigator, TMIST
Professor in Residence of Radiology, Beth Israel Deaconess Medical Center
Constantine A. Gatsonis, PhD
Henry Ledyard Goddard University Professor of Biostatistics, Chair, Department of Biostatistics, Brown University
Peter J. O'Dwyer, MD
Group co-chair, director, ECOG-ACRIN Cancer Research Group, Developmental Therapeutics Program, Abramson Cancer Center, professor of medicine, Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Mitchell D. Schnall, MD, PhD
Group co-chair, ECOG-ACRIN Cancer Research Group; Eugene P. Pendergrass Professor of Radiology, The Perelman School of Medicine, University of Pennsylvania
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
By Katie Goldberg
Capitol Hill

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
By Jacquelyn Cobb and Claire Marie Porter
Clinical

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH. 
By Jacquelyn Cobb
Byline
Etta D. Pisano, MD
Principal investigator, TMIST
Professor in Residence of Radiology, Beth Israel Deaconess Medical Center
Constantine A. Gatsonis, PhD
Henry Ledyard Goddard University Professor of Biostatistics, Chair, Department of Biostatistics, Brown University
Peter J. O'Dwyer, MD
Group co-chair, director, ECOG-ACRIN Cancer Research Group, Developmental Therapeutics Program, Abramson Cancer Center, professor of medicine, Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Mitchell D. Schnall, MD, PhD
Group co-chair, ECOG-ACRIN Cancer Research Group; Eugene P. Pendergrass Professor of Radiology, The Perelman School of Medicine, University of Pennsylvania
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account